Penicillamine revisited: Historic overview and review of the clinical uses and cutaneous adverse effects

American Journal of Clinical Dermatology

Volumn 14, Issue 3, 2013, Pages 223-233

  Ishak, Rim ^a   Abbas, Ossama ^a  

^a AMERICAN UNIVERSITY OF BEIRUT   (Lebanon)

Author keywords

[No Author keywords available]

Indexed keywords

CERULOPLASMIN; COPPER; CORTICOSTEROID; HLA A1 ANTIGEN; HLA B8 ANTIGEN; HLA DR1 ANTIGEN; HLA DR3 ANTIGEN; HLA DR4 ANTIGEN; PENICILLAMINE; PROTEIN BCL 2; PROTEIN P53;

AGRANULOCYTOSIS; ANOREXIA; ANTIANGIOGENIC ACTIVITY; APLASTIC ANEMIA; APOPTOSIS; CYSTINURIA; DERMATOMYOSITIS; DIARRHEA; DIPLOPIA; DRUG CONTRAINDICATION; DRUG INDUCED DISEASE; DRUG WITHDRAWAL; DYSPEPSIA; ELASTIC FIBER; ELASTOSIS PERFORANS SERPIGINOSA; EOSINOPHILIC FASCIITIS; EPIDERMOLYSIS BULLOSA ACQUISITA; GLIOBLASTOMA; HEMATURIA; HISTOPATHOLOGY; HUMAN; LEUKOPENIA; LICHEN PLANUS; LOW DRUG DOSE; LUPUS LIKE SYNDROME; METASTATIC MELANOMA; MUCOUS MEMBRANE PEMPHIGOID; NAUSEA; NEPHRITIS; NONHUMAN; OVERALL SURVIVAL; OXIDATIVE STRESS; PEMPHIGUS; PHOTOPHOBIA; PRIMARY BILIARY CIRRHOSIS; PRIORITY JOURNAL; PROTEINURIA; PSEUDOXANTHOMA ELASTICUM; REVIEW; RHEUMATOID ARTHRITIS; SCLERODERMA; SKIN DISEASE; SYSTEMIC SCLEROSIS; TASTE DISORDER; THROMBOCYTOPENIA; VOMITING; WILSON DISEASE;

CHELATING AGENTS; HUMANS; PENICILLAMINE; SKIN DISEASES;

EID: 84878749327     PISSN: 11750561     EISSN: 11791888     Source Type: Journal    
DOI: 10.1007/s40257-013-0022-z     Document Type: Review

References (149)

1. Walshe JM. Penicillamine, a new oral therapy for Wilson's disease. Am J Med. 1956;21(4):487-95.
2. Abraham EPC, Baker W, Robinson R. Penicillamine, a characteristic degradation product of penicillin. Nature. 1943;151:107-10.
3. Weigert WM, Offermanns H, Scherberich P. d-Penicillamine: production and properties. Angew Chem Int Ed Engl. 1975;14(5):330-6.
4. Kukovetz WR, Beubler E, Kreuzig F, et al. Bioavailability and pharmacokinetics of d-penicillamine. J Rheumatol. 1983;10(1):90-4.
5. Netter P, Bannwarth B, Pere P, et al. Clinical pharmacokinetics of d-penicillamine. Clin Pharmacokinet. 1987;13(5):317-33.
6. Perrett D. The metabolism and pharmacology of d-penicillamine in man. J Rheumatol. Suppl. 1981;7:41-50.
7. Kyogoku K, Inoue K, Otake T, et al. Determination of d-penicillamine and its metabolites in blood and urine. Yakugaku Zasshi. 1982;102(4):322-7.
8. Waring RH, Mitchell SC. The metabolism of 35S-d-penicillamine in man. Xenobiotica. 1988;18(2):235-44.
9. Bialy-Golan A, Brenner S. Penicillamine-induced bullous dermatoses. J Am Acad Dermatol. 1996;35(5 Pt 1):732-42.
10. Capell HA Madhok R, Zoma A, et al. Is determination of sulfoxidation status a useful predictor of penicillamine toxicity in RA patients? Proceedings of the third world conference on clinical pharmacology and therapeutics; 1986 Jul-Aug; Stockholm: abstract no. 658.
11. Levy RS, Fisher M, Alter JN. Penicillamine: review and cutaneous manifestations. J Am Acad Dermatol. 1983;8(4):548-58.
12. Boulding JE, Baker RA. The treatment of metal poisoning with penicillamine. Lancet. 1957;2:985.
13. Derk CT, Huaman G, Jimenez SA. A retrospective randomly selected cohort study of d-penicillamine treatment in rapidly progressive diffuse cutaneous systemic sclerosis of recent onset. Br J Dermatol. 2008;158(5):1063-8.
14. Jain S, Scheuer PJ, Samourian S, et al. A controlled trial of d-penicillamine therapy in primary biliary cirrhosis. Lancet. 1977;1(8016):831-4.
15. Phelps DL, Lakatos L, Watts JL. d-Penicillamine for preventing retinopathy of prematurity in preterm infants. Cochrane Database Syst Rev. 2001;(1):CD001073.
16. Tandon M, Dutta S, Dogra MR, et al. Oral d-penicillamine for the prevention of retinopathy of prematurity in very low birth weight infants, a randomized placebo controlled trial. Acta Pediatrica. 2010;99(9):1324-8.
17. Klingenberg SL, Chen W. d-penicillamine for primary sclerosing cholangitis. Cochrane Database Syst Rev. 2006;(1):CD004182.
18. Mayou BJ. d-Penicillamine in the treatment of keloids. Br J Dermatol. 1981;105(1):87-9.
19. Beer WE, Lyle WH. Penicillamine for the treatment of Darier's disease and other disorders of keratin formation. Lancet. 1966;2(7477):1337-40.
20. Savage A, Hinton C, Tribe CR. Experimental murine amyloidosis II: effect of penicillamine therapy. Br J Exp Pathol. 1980;61(5):471-3.
21. Corrigan JJ Jr, Damiano ML, Leissinger C, et al. Treatment of chronic haemophilic synovitis in humans with d-penicillamine. Haemophilia. 2003;9(1):64-8.
22. Kaya TI, Kokturk A, Tursen U, et al. d-Penicillamine treatment for lipoid proteinosis. Pediatr Dermatol. 2002;19(4):359-62.
23. Nagler R, Cohen S, Savulescu D, et al. Penicillamine as a potent protector against injurious effects of cigarette smoke in aerodigestive tract cancer. Oncology. 2010;78(1):12-9.
24. Brem S. Angiogenesis and cancer control: from concept to therapeutic trial. Cancer Control. 1999;6(5):436-58.
25. Gupte A, Mumper RJ. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat Rev. 2009;35(1):32-46.
26. Brem S, Grossman SA, Carson KA, et al. Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro Oncol. 2005;7(3):246-53.
27. Squitti R, Rossini PM, Cassetta E, et al. d-Penicillamine reduces serum oxidative stress in Alzheimer's disease patients. Eur J Clin Invest. 2002;32(1):51-9.
28. Harris ED Jr, Sjoerdsma A. Effect of penicillamine on human collagen and its possible application to treatment of scleroderma. Lancet. 1966;2(7471):996-9.
29. Nimni ME. Mechanism of inhibition of collagen crosslinking by penicillamine. Proc R Soc Med. 1977;70(Suppl. 3):65-72.
30. Steen VD, Medsger TA Jr, Rodnan GP. d-Penicillamine therapy in progressive systemic sclerosis (scleroderma): a retrospective analysis. Ann Intern Med. 1982;97(5):652-9.
31. Jimenez SA, Sigal SH. A 15-year prospective study of treatment of rapidly progressive systemic sclerosis with d-penicillamine. J Rheumatol. 1991;18(10):1496-503.
32. Rodnan GP. Progressive systemic sclerosis and penicillamine. J Rheumatol Suppl. 1981;7:116-20.
33. Steen VD, Medsger TA Jr. Improvement in skin thickening in systemic sclerosis associated with improved survival. Arthritis Rheum. 2001;44(12):2828-35.
34. Medsger TA Jr, Lucas M, Wildy KS, et al. d-Penicillamine in systemic sclerosis? Yes! Scand J Rheumatol. 2001;30(4):192-4.
35. Clements PJ, Hurwitz EL, Wong WK, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum. 2000;43(11):2445-54.
36. Clements PJ, Furst DE, Wong WK, et al. High-dose versus low-dose d-penicillamine in early diffuse systemic sclerosis: analysis of a two-year, double-blind, randomized, controlled clinical trial. Arthritis Rheum. 1999;42(6):1194-203.
37. Falanga V, Medsger TA Jr. d-Penicillamine in the treatment of localized scleroderma. Arch Dermatol. 1990;126(5):609-12.
38. Moynahan EJ. d(-)Penicillamine in morphoea (localised scleroderma). Lancet. 1973;I(7800):428-9.
39. Tandon M, Dutta S, Dogra MR. Penicillamine in the treatment of morphoea and keloid in children. Postgrad Med J. 1974;50(Suppl. 2):39-41.
40. Sharifian M, Sari-Aslani F, Hemmatinejad B, et al. d-Penicillamine, a potent melanogenesis inhibitor, lacks any depigmenting effect on black guinea pig skin: the first randomized, evaluated blinded vehicle-controlled, in vivo study. Acta Dermatoven APA. 2011;20(2):51-3.
41. Brozyna AA, VanMiddlesworth L, Slomiski AT. Inhibition of melanogenesis as a radiation senstitizer for melanoma therapy. Int J Cancer. 2008;123:1448-56.
42. Qiao S, Cabello C, Lamore SD, et al. d-Penicillamine targets metastatic melanoma cells with induction of the unfolded protein response (UPR) and Noxa (PMAIP1)-dependent mitochondrial apoptosis. Apoptosis. 2012;17(10):1079-94.
43. Grisanti MW, Moore TL, Osborn TG, et al. Eosinophilic fasciitis in children. Semin Arthritis Rheum. 1989;19(3):151-7.
44. Caspi D, Fishel R, Varon M, et al. Multisystem presentation of eosinophilic fasciitis. Rheumatol Rehabil. 1982;21(4):218-21.
45. Martínez-Osuna P, Wallach PM, Seleznick MJ, et al. Treatment of the eosinophilia-myalgia syndrome. Semin Arthritis Rheum. 1991;21(2):110-21.
46. Stork J, Němcová D, Hoza J, et al. Eosinophilic fasciitis in an adolescent girl with lymphadenopathy and vitiligo-like and linear scleroderma-like changes: a case report. Clin Exp Rheumatol. 1996;14(3):337-41.
47. Bischoff L, Derk CT. Eosinophilic fasciitis: demographics, disease pattern and response to treatment: report of 12 cases and review of the literature. Int J Dermatol. 2008;47(1):29-35.
48. Epler GR, Snider GL, Gaensler EA, et al. Bronchiolitis and bronchitis in connective tissue disease: a possible relationship to the use of penicillamine. JAMA. 1979;242(6):528-32.
49. Kovalev VM, Krivenko ZF. New aspects of the pathogenesis and treatment of Schulmann's eosinophilic fasciitis. Vestn Dermatol Venerol. 1989;12:13-5.
50. Farrington ML, Haas JE, Nazar-Stewart V, et al. Eosinophilic fasciitis in children frequently progresses to scleroderma-like cutaneous fibrosis. J Rheumatol. 1993;20(1):128-32.
51. Coyle HE, Chapman RS. Eosinophilic fasciitis (Shulman syndrome) in association with morphoea and systemic sclerosis. Acta Derm Venereol. 1980;60(2):181-2.
52. Manzini CU, Sebastiani M, Giuggioli D, et al. d-Penicillamine in the treatment of eosinophilic fasciitis: case reports and review of the literature. Clin Rheumatol. 2012;31(1):183-7.
53. Shiokawa Y, Horiuchi Y, Honma M, et al. Clinical evaluation of d-penicillamine by multicentric double-blind comparative study in chronic rheumatoid arthritis. Arthritis Rheum. 1977; 20 (8):1464-72.
54. Garlepp MI, Dawkins RL, Christiansen FT. HLA antigens and acetylcholine receptor antibodies in penicillamine induced myasthenia gravis. Br Med J (Clin Res Ed). 1983;286(6375):1442-3.
55. Delamere JP, Jobson S, Mackintosh LP, et al. Penicillamine-induced myasthenia in rheumatoid arthritis: its clinical and genetic features. Ann Rheum Dis. 1983;42(5):500-4.
56. Stockman A, Zilko PJ, Major GA, et al. Genetic markers in rheumatoid arthritis relationship to toxicity from d-penicillamine. J Rheumato. 1986;13(2):269-73.
57. Bird ED. Aplastic anaemia following penicillamine. Postgrad Med J. 1974;50(Suppl. 2):73-4.
58. Siafakas CG, Jonas MM, Alexander S, et al. Early onset of nephrotic syndrome after treatment with d-penicillamine in a patient with Wilson's disease. Am J Gastroenterol. 1998;93(12):2544-6.
59. Bienaime F, Clerbaux G, Plaisier E, et al. d-Penicillamine-induced ANCA-associated crescentic glomerulonephritis in Wilson disease. Am J Kidney Dis. 2007;50(5):821-5.
60. Derk CT, Jimenez SA. Goodpasture-like syndrome induced by d-penicillamine in a patient with systemic sclerosis: report and review of the literature. J Rheumatol. 2003;30(7):1616-20.
61. Sharma R, Jain S, Kher V. ANCA-associated Goodpastures syndrome in a patient with rheumatoid arthritis on penicillamine. Indian J Nephrol. 2012; 22(1):45-47.
62. DeSilva RN, Eastmond CJ. Management of proteinuria secondary to penicillamine therapy in rheumatoid arthritis. Clin Rheumatol. 1992;11:216-9.
63. Kay A. European league against rheumatism study of adverse reactions to d-penicillamine. Br J Rheumatol. 1986;25:193-8.
64. Bacon PA, Tribe CR, Mackenzie JC, et al. Penicillamine nephropathy in rheumatoid arthritis. QJM. 1976;80:661-84.
65. Habib GS, Saliba W, Nashashibi M, et al. Penicillamine and nephrotic syndrome. Eur J Intern Med. 2006;17(5):343-8.
66. Shettar SP, Chattopadhyay C, Wolstenholme RJ, et al. Diffuse alveolitis on a small dose of penicillamine. Br J Rheumatol. 1984;23(3):220-4.
67. Kato Y, Naito Y, Narita Y, et al. d-Penicillamine-induced myasthenia gravis in a case of eosinophilic fasciitis. J Neurol Sci. 1997;146(1):85-6.
68. Poulas K, Koutsouraki E, Kordas G, et al. Anti-MuSK- and anti-AChR-positive myasthenia gravis induced by d-penicillamine. J Neuroimmunol. 2012;250(1-2):94-8.
69. Tchebiner JZ. Breast enlargement induced by d-penicillamine. Ann Pharmacother. 2002;36(3):444-5.
70. Bertrand JL, Rousset H, Queneau P, et al. Autoimmune thyroiditis: a rare complication of treatment with d-penicillamine (author's transl). Therapie. 1981;36(3):333-6.
71. Chappel R, Willems J. d-Penicillamine-induced myositis in rheumatoid arthritis. Clin Rheumatol. 1996;15(1):86-7.
72. Herrero JL, Muñoz Bertrán E, Ortega González I, et al. Myelopathy secondary to copper deficiency as a complication of treatment of Wilson's disease. Gastroenterol Hepatol. 2012;35(10):704-7.
73. Pass F, Goldfischer S, Sternlieb I, et al. Elastosis perforans serpiginosa during penicillamine therapy for Wilson disease. Arch Dermatol. 1973;108(5):713-5.
74. Bolognia JL, Braverman I. Pseudoxanthoma-elasticum-like skin changes induced by penicillamine. Dermatology. 1992;184(1):12-8.
75. Greer KE, Askew FC, Richardson DR. Skin lesions induced by penicillamine: occurrence in a patient with hepatolenticular degeneration (Wilson disease). Arch Dermatol. 1976;112(9):1267-9.
76. Davis W. Wilson's disease and penicillamine-induced anetoderma. Arch Dermatol. 1977;113:976.
77. Burge S, Ryan T. Penicillamine-induced pseudo-pseudoxanthoma elasticum in a patient with rheumatoid arthritis. Clin Exp Dermatol. 1988;13(4):255-8.
78. Coatesworth AP, Darnton SJ, Green RM, et al. A case of systemic pseudo-pseudoxanthoma elasticum with diverse symptomatology caused by long-term penicillamine use. J Clin Pathol. 1998;51(2):169-71.
79. Lewis BK, Chern PL, Stone MS. Penicillamine-induced elastosis of the mucosal lip. J Am Acad Dermatol. 2009;60(4):700-3.
80. Rath N, Bhardwaj A, Kar HK, et al. Penicillamine induced pseudoxanthoma elasticum with elastosis perforans serpiginosa. Indian J Dermatol Venereol Leprol. 2005;71(3):182-5.
81. Becuwe C, Dalle S, Ronger-Savle S, et al. Elastosis perforans serpiginosa associated with pseudo-pseudoxanthoma elasticum during treatment of Wilson's disease with penicillamine. Dermatology. 2005;210(1):60-3.
82. Meyrick Thomas RH, Kirby JD. Elastosis perforans serpiginosa and pseudoxanthoma elasticum-like skin change due to d-penicillamine. Clin Exp Dermatol. 1985;10(4):386-91.
83. Rosen LB, Muellenhoff M, Tran TT, et al. Elastosis perforans serpiginosa secondary to d-penicillamine therapy with coexisting cutis laxa. Cutis. 2005;76(1):49-53.
84. Hill VA, Seymour CA, Mortimer PS. Pencillamine-induced elastosis perforans serpiginosa and cutis laxa in Wilson's disease. Br J Dermatol. 2000;142(3):560-1.
85. Amichai B, Rotem A, Metzker A. d-Penicillamine-induced elastosis perforans serpiginosa and localized cutis laxa in a patient with Wilson's disease. Isr J Med Sci. 1994;30(8):667-9.
86. Iozumi K, Nakagawa H, Tamaki K. Penicillamine-induced degenerative dermatoses: report of a case and brief review of such dermatoses. J Dermatol. 1997;24(7):458-65.
87. Bardach H, Gebhart W, Niebauer G. "Lumpy-bumpy" elastic fibers in the skin and lungs of a patient with a penicillamine-induced elastosis perforans serpiginosa. J Cutan Pathol. 1979;6(4):243-52.
88. Bergman R, Friedman-Birnbaum R, Ludatscher R, et al. An ultrastructural study of the reactive type of elastosis perforans serpiginosa. Arch Dermatol. 1987;123(9):1127-9.
89. Mehregan AH. Elastosis perforans serpiginosa: a review of the literature and report of 11 cases. Arch Dermatol. 1968;97(4):381-93.
90. Price RG, Prentice RS. Penicillamine-induced elastosis perforans serpiginosa: tip of the iceberg? Am J Dermatopathol. 1986;8(4):314-20.
91. Atzori L, Pinna AL, Pau M, et al. d-Penicillamine elastosis perforans serpiginosa: description of two cases and review of the literature. Dermatol Online J. 2011;17(4):3.
92. Tovaru S, Parlatescu I, Dumitriu AS, et al. Oral complications associated with d-penicillamine treatment for Wilson disease: a clinicopathologic report. J Periodontol. 2010;81(8):1231-6.
93. Roest MA, Ratnavel R. Elastosis perforans serpiginosa of the penis. BJU Int. 2003;91(4):427.
94. Le Saux O, Urban Z, Tschuch C, et al. Mutations in a gene encoding an ABC transporter cause pseudoxanthoma elasticum. Nat Genet. 2000;25(2):223-7.
95. Rayatt S, Pandey U, Khanna A. Familial pseudo pseudoxanthoma elasticum. J Plast Reconstr Aesthet Surg. 2006;59(10):1127-9.
96. Meyrick Thomas RH, Light N, Stephens AD, et al. Pseudoxanthoma elasticum-like skin changes induced by penicillamine. J R Soc Med. 1984;77(9):794-8.
97. Walshe JM. Congenital cutis laxa and maternal d-penicillamine. Lancet. 1979;2(8134):144-5.
98. Linares A, Zarranz JJ, Rodriguez-Alarcon J, et al. Reversible cutis laxa due to maternal d-penicillamine treatment. Lancet. 1979;2(8132):43.
99. Pinter R, Hogge WA, McPherson E. Infant with severe penicillamine embryopathy born to a woman with Wilson disease. Am J Med Genet A. 2004;128A(3):294-8.
100. Zone J, Ward J, Boyce E, et al. Penicillamine-induced pemphigus. JAMA. 1982;247(19):2705-7.
101. Dawkins RL, Zilko PJ, Carrano J, et al. Immunobiology of d-penicillamine. J Rheumatol Suppl. 1981;7:56-61.
102. Epstein O, De Villiers D, Jain S, et al. Reduction of immune complexes and immunoglobulins induced by d-penicillamine in primary biliary cirrhosis. N Engl J Med. 1979;300(6):274-8.
103. Huskisson EC, Berry H. Some immunological changes in rheumatoid arthritis among patients receiving penicillamine and gold. Postgrad Med J. 1974;50(Suppl. 2):59-61.
104. Degos R, Touraine R, Belaich S, et al. Pemphigus in a patient treated with penicillamine for Wilson's disease. Bull Soc Fr Dermatol Syphiligr. 1969;76(6):751-3.
105. Mutasim DF, Pelc NJ, Anhalt GJ. Drug-induced pemphigus. Dermatol Clin. 1993;11(3):463-71.
106. Ruocco V, Sacerdoti G. Pemphigus and bullous pemphigoid due to drugs. Int J Dermatol. 1991;30(5):307-12.
107. Penas PF, Buezo GF, Carvajal I, et al. D-Penicillamine-induced pemphigus foliaceus with autoantibodies to desmoglein-1 in a patient with mixed connective tissue disease. J Am Acad Dermatol. 1997;37(1):121-3.
108. Toth GG, Jonkman MF. Successful treatment of recalcitrant penicillamine-induced pemphigus foliaceus by low-dose intravenous immunoglobulins. Br J Dermatol. 1999;141(3):583-5.
109. Cetkovska P, Pizinger K, Skalova A. Epidermolysis bullosa acquisita-like reaction associated with penicillamine therapy for sclerodermatous graft-versus-host disease. J Am Acad Dermatol. 2003;49(6):1157-9.
110. Szegedi A, Suranyi P, Szucs G, et al. D-Penicillamine-induced pemphigus vulgaris in a patient with scleroderma-rheumatoid arthritis overlap syndrome. Acta Derm Venereol. 2004;84(4):318-9.
111. Popadic S, Skiljevic D, Medenica L. Bullous pemphigoid induced by penicillamine in a patient with Wilson disease. Am J Clin Dermatol. 2009;10(1):36-8.
112. Sugita K, Hirokawa H, Izu K, et al. d-Penicillamine-induced pemphigus successfully treated with combination therapy of mizoribine and prednisolone. J Dermatolog Treat. 2004;15(4):214-7.
113. Ogata K, Nakajima H, Ikeda M, et al. Drug-induced pemphigus foliaceus with features of pemphigus vulgaris. Br J Dermatol. 2001;144(2):421-2.
114. Shapiro M, Jimenez S, Werth VP. Pemphigus vulgaris induced by d-penicillamine therapy in a patient with systemic sclerosis. J Am Acad Dermatol. 2000;42(2 Pt 1):297-9.
115. Jan V, Callens A, Machet L, et al. d-Penicillamine-induced pemphigus, polymyositis and myasthenia. Ann Dermatol Venereol. 1999;126(2):153-6.
116. Pegum JS, Pembroke AC. Benign mucous-membrane pemphigoid associated with penicillamine treatment. Br Med J. 1977;1(6074):1473.
117. Rasmussen HB, Jepsen LV, Brandrup F. Penicillamine-induced bullous pemphigoid with pemphigus-like antibodies. J Cutan Pathol. 1989;16(3):154-7.
118. Weller R, White MI. Penicillamine in the etiology of bullous pemphigoid. Ann Pharmacother. 1998;32(12):1368.
119. Weller R, White MI. Bullous pemphigoid and penicillamine. Clin Exp Dermatol. 1996;21(2):121-2.
120. Brenner S, Bialy-Golan A, Ruocco V. Drug-induced pemphigus. Clin Dermatol. 1998;16(3):393-7.
121. Marsden RA, Vanhegan RI, Walshe M, et al. Pemphigus foliaceus induced by penicillamine. Br Med J. 1976;2(6049):1423-4.
122. Santa Cruz DJ, Prioleau PG, Marcus MD, et al. Pemphigus-like lesions induced by d-penicillamine: analysis of clinical, histopathological, and immunofluorescence features in 34 cases. Am J Dermatopathol. 1981 Spring;3(1):85-92.
123. Hay KD, Muller HK, Reade PC. d-Penicillamine-induced mucocutaneous lesions with features of pemphigus. Oral Surg Oral Med Oral Pathol. 1978;45(3):385-95.
124. Korman NJ, Eyre RW, Zone J, et al. Drug-induced pemphigus: autoantibodies directed against the pemphigus antigen complexes are present in penicillamine and captopril-induced pemphigus. J Invest Dermatol. 1991;96(2):273-6.
125. Nagao K, Tanikawa A, Yamamoto N, et al. Decline of anti-desmoglein 1 IgG ELISA scores by withdrawal of d-penicillamine in drug-induced pemphigus foliaceus. Clin Exp Dermatol. 2005;30(1):43-5.
126. Troy JL, Silvers DN, Grossman ME, et al. Penicillamine-associated pemphigus: is it really pemphigus? J Am Acad Dermatol. 1981;4(5):547-55.
127. Wolf R, Brenner S. An active amide group in the molecule of drugs that induce pemphigus: a casual or causal relationship? Dermatology. 1994;189(1):1-4.
128. Brown MD, Dubin HV. Penicillamine-induced bullous pemphigoid-like eruption. Arch Dermatol. 1987;123(9):1119-20.
129. Lever LR, Wojnarowska F. Benign mucous membrane pemphigoid and penicillamine. Br J Dermatol. 1985;113:88-9.
130. Shuttleworth D, Graham-Brown RA, Hutchinson PE, et al. Cicatricial pemphigoid in d-penicillamine treated patients with rheumatoid arthritis: a report of three cases. Clin Exp Dermatol. 1985;10(4):392-7.
131. Shuttleworth DGBR. Cicatricial pemphigoid in a d-penicillamine treated patient with rheumatoid arthritis. Br J Dermatol. 1985;113:89-90.
132. Peyri J, Servitje O, Ribera M, et al. Cicatricial pemphigoid in a patient with rheumatoid arthritis treated with d-penicillamine. J Am Acad Dermatol. 1986;14(4):681.
133. Marti-Huguet T, Quintana M, Cabiro I. Cicatricial pemphigoid associated with d-penicillamine treatment. Arch Ophthalmol. 1989;107(8):1115.
134. Rimbaud P, Mirouze J, Mary P, et al. Syndrome of "epidermolysis bullosa with epidermal cyst" appearing during Wilson's disease treated with penicillamine. Bull Soc Fr Dermatol Syphiligr. 1970;77(4):484-6.
135. Beer WE, Cooke KB. Epidermolysis bullosa induced by penicillamine. Br J Dermatol. 1967;79(2):123-5.
136. Godar JM, Norins AL. Vesicular lesions in a woman with progressive systemic sclerosis: penicillamine-induced intradermal vesicles: an example of human lathyrism. Arch Dermatol. 1992;128(7):977-8, 980-1.
137. Walshe JM. Toxic reactions to penicillamine in patients with Wilson's disease. Postgrad Med J. 1968;Suppl:6-8.
138. Camus JP, Homberg JC, Crouzet J, et al. Autoantibody formation in d-penicillamine-treated rheumatoid arthritis. J Rheumatol Suppl. 1981;7:80-3.
139. Oliver I, Liberman UA, DeVries A. Lupus-like syndrome induced by penicillamine in cystinuria. JAMA. 1972;220(4):588.
140. Walshe JM. Penicillamine and the SLE syndrome. J Rheumatol Suppl. 1981;7:155-60.
141. Sternlieb I, Fisher M, Scheinberg IH. Penicillamine-induced skin lesions. J Rheumatol Suppl. 1981;7:149-54.
142. Simpson NB, Golding JR. Dermatomyositis induced by penicillamine. Acta Derm Venereol. 1979;59(6):543-4.
143. Petersen J, Halberg P, Hojgaard K, et al. Penicillamine-induced polymyositis-dermatomyositis. Scand J Rheumatol. 1978;7(2):113-7.
144. Fernandes L, Swinson DR, Hamilton EB. Dermatomyositis complicating penicillamine treatment. Ann Rheum Dis. 1977;36(1):94-5.
145. Schraeder PL, Peters HA, Dahl DS. Polymyositis and penicillamine. Arch Neurol. 1972;27(5):456-7.
146. van de Staak WJ, Cotton DW, Jonckheer-Venneste MM, et al. Lichenoid eruption following penicillamine: a case report with some biochemical observations. Dermatologica. 1975;150(6):372-4.
147. Seehafer JR, Rogers RS, Fleming CR, et al. Lichen planus-like lesions caused by penicillamine in primary biliary cirrhosis. Arch Dermatol. 1981;117(3):140-2.
148. Bennett RA, Harbilas E. Wilson's disease with aseptic meningitis and penicillamine-related cheilosis. Arch Intern Med. 1967;120(3):374-6.
149. Rimbaud P, Mirouze J, Mary P, et al. Dermatological complications during treatment of Wilsons disease with d-penicillamine. Med Chir Dig. 1973;2(1):3-8.